A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
作者: Emilie LereclusMira ToutAlban GiraultNadine BaroukhMorgane CauletChristophe BorgOlivier BouchéDavid TernantGilles PaintaudThierry LecomteWilliam Raoul
作者单位: 1Université François-Rabelais de Tours, CNRS, GICC UMR 7292, UFR de médecine, BP 3223
2CHRU de Tours, Department of Hepato-Gastroenterology and Digestive Oncology
3University Hospital
4University Hospital Robert Debré
5CHRU de Tours, Laboratory of Pharmacology-Toxicology
6Université François
刊名: BMC Cancer, 2017, Vol.17 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s12885-017-3210-z
关键词: BevacizumabVascular endothelial growth factorTh17-related cytokinesIL-17 polymorphismsMetastatic colorectal cancerSurvival analysis: score
英文摘要: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy.
原始语种摘要: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy.
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:3.333 (2012)

×
关键词翻译
关键词翻译
  • colorectal 结肠直肠的
  • survival 生存
  • metastatic 新陈代谢的
  • treated 加工的
  • chemotherapy 化学疗法
  • cancer 癌症
  • association 联合
  • regimen 生活制度
  • serum 血清
  • progression 级数